Our results also suggest that CNN1 serves as a double-edged sword between the physiological and pathological conditions, or between cancer initiation and progression, and it might also vary on the type of cancer, which might provide precautions and evidence for CNN1-targeted drug development and its clinical application. The gene discussed is CNN1; the disease is cancer.